Literature DB >> 27879483

Comparison of ex vivo stability of copeptin and vasopressin.

Judith E Heida1, Lianne S M Boesten1, Esmée M Ettema1, Anneke C Muller Kobold1, Casper F M Franssen1, Ron T Gansevoort1, Debbie Zittema1.   

Abstract

BACKGROUND: Copeptin, part of the vasopressin precursor, is increasingly used as marker for vasopressin and is claimed to have better ex vivo stability. However, no study has directly compared the ex vivo stability of copeptin and vasopressin.
METHODS: Blood of ten healthy volunteers was collected in EDTA tubes. Next, we studied the effect of various pre-analytical conditions on measured vasopressin and copeptin levels: centrifugation speed, short-term storage temperature and differences between whole blood and plasma, long-term storage temperature and repeated freezing and thawing. The acceptable change limit (ACL), indicating the maximal percentage change that can be explained by assay variability, was used as cut-off to determine changes in vasopressin and copeptin.
RESULTS: The ACL was 25% for vasopressin and 19% for copeptin. Higher centrifugation speed resulted in lower vasopressin levels, whereas copeptin concentration was unaffected. In whole blood, vasopressin was stable up to 2 h at 25°C and 6 h at 4°C. In plasma, vasopressin was stable up to 6 h at 25°C and 24 h at 4°C. In contrast, copeptin was stable in whole blood and plasma for at least 24h at both temperatures. At -20°C, vasopressin was stable up to 1 month and copeptin for at least 4 months. Both vasopressin and copeptin were stable after 4 months when stored at -80°C and -150°C. Vasopressin concentration decreased after four freeze-thaw cycles, whereas copeptin concentration was unaffected.
CONCLUSION: Vasopressin levels were considerably affected by pre-analytical conditions, while copeptin levels were stable. Therefore, a strict sample handling protocol for measurement of vasopressin is recommended.

Entities:  

Keywords:  copeptin; ex vivo; stability; vasopressin

Mesh:

Substances:

Year:  2017        PMID: 27879483     DOI: 10.1515/cclm-2016-0559

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population.

Authors:  Ray El Boustany; Irina Tasevska; Esther Meijer; Lyanne M Kieneker; Sofia Enhörning; Guillaume Lefèvre; Kamel Mohammedi; Michel Marre; Frédéric Fumeron; Beverley Balkau; Nadine Bouby; Lise Bankir; Stephan Jl Bakker; Ronan Roussel; Olle Melander; Ron T Gansevoort; Gilberto Velho
Journal:  JCI Insight       Date:  2018-07-12

2.  Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Authors:  Ron T Gansevoort; Maatje D A van Gastel; Arlene B Chapman; Jaime D Blais; Frank S Czerwiec; Eiji Higashihara; Jennifer Lee; John Ouyang; Ronald D Perrone; Katrin Stade; Vicente E Torres; Olivier Devuyst
Journal:  Kidney Int       Date:  2019-03-09       Impact factor: 10.612

3.  Prognostic value of copeptin in patients with acute myocardial infarction treated with percutaneous coronary intervention: a prospective cohort study.

Authors:  Marta Roczek-Janowska; Michal Kacprzak; Malgorzata Dzieciol; Marzenna Zielinska; Krzysztof Chizynski
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

4.  Plasma vasopressin levels are closely associated with fetal hypotension and neuronal injury after hypoxia-ischemia in near-term fetal sheep.

Authors:  Christopher A Lear; Michi Kasai; Paul P Drury; Joanne O Davidson; Etsuko Miyagi; Laura Bennet; Alistair J Gunn
Journal:  Pediatr Res       Date:  2020-03-17       Impact factor: 3.756

5.  The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial.

Authors:  Judith E Heida; Ron T Gansevoort; Vicente E Torres; Olivier Devuyst; Ronald D Perrone; Jennifer Lee; Hui Li; John Ouyang; Arlene B Chapman
Journal:  J Am Soc Nephrol       Date:  2021-04-22       Impact factor: 14.978

6.  Improving Science by Overcoming Laboratory Pitfalls With Hormone Measurements.

Authors:  Jacquelien J Hillebrand; Wjera V Wickenhagen; Annemieke C Heijboer
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

7.  Copeptin in Growth Hormone-Treated Patients.

Authors:  Anna Sjöström; Simona I Chisalita; Charlotte Höybye
Journal:  J Clin Med       Date:  2022-09-20       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.